Kinoxis Therapeutics develops small molecule therapeutics that target the oxytocin receptor to enhance social functioning and address social dysfunction in neurological and psychiatric disorders. Their lead candidate, KNX100, is designed for substance use disorders and has completed Phase I clinical trials, aiming to improve recovery outcomes for affected individuals.
Funding
$22.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Social dysfunction is a common and debilitating symptom across various developmental, psychiatric, and neurological disorders, significantly hindering recovery and overall quality of life. Current treatments often fail to adequately address the underlying social deficits associated with these conditions.
Solution
Kinoxis Therapeutics is developing small molecule therapeutics that target social pathways in the brain, with a focus on the oxytocin receptor, to enhance social functioning. Their lead candidate, KNX100, employs a novel, undisclosed mechanism of action to treat substance use disorders and agitation/aggression in neurodegenerative and neurodevelopmental disorders. By rebalancing activity in malfunctioning social pathways, Kinoxis aims to restore normal social functioning and improve treatment outcomes for individuals affected by these disorders. Their approach offers a potential breakthrough by directly addressing the social deficits that impede recovery and well-being.
Target Audience
The primary target audience includes individuals suffering from substance use disorders, neurodegenerative disorders, and neurodevelopmental disorders who experience social dysfunction, as well as the healthcare professionals treating these conditions.
Features
- KNX100: A novel small molecule therapeutic for substance use disorders and agitation/aggression.
- Oxytocin receptor-targeted compounds: Selective partial agonists and positive allosteric modulators.
- Focus on rebalancing activity in brain pathways involved in social behavior.
- First-in-class therapeutics designed to enhance social functioning.